New approaches for the identification of antivirulence agents based on LsrK inhibition : from assay development to screening campaigns by Gatta, Viviana
1 
 
Division of Pharmaceutical Biosciences 
Faculty of Pharmacy 
University of Helsinki 
 
Doctoral School in Health Sciences 




New approaches for the identification of antivirulence 
agents based on LsrK inhibition: 











To be presented with the permission of the Faculty of Pharmacy,     
University of Helsinki, for public examination in room 1015 (Biocentre 2, 






Professor Päivi Tammela  
Division of Pharmaceutical Biosciences  
Faculty of Pharmacy  
University of Helsinki, Finland 
 
 
Associate Professor Martin Welch  
Department of Biochemistry 
University of Cambridge, UK 
 
Reviewers  
Associate Professor Barbara Cellini 
Department of Experimental Medicine 




Professor Lari Lehtiö 
Faculty of Biochemistry and Molecular Medicine 
University of Oulu, Finland 
 
 
                                                         
Opponent  
 
Professor Karina Xavier 






















































ISBN 978-951-51-6606-7 (paperback) 























To Gino, my grandfather. 
you have always believed in me 
you have always been with me 


































2. Review of literature..................................................................................................15 
2.1. Resistance to antibiotics...................................................................................15 
2.2. MDR and XDR pathogens: current treatments and new perspectives.....17 
2.3. Antivirulence strategies...................................................................................19 
2.3.2. Quorum sensing inhibition…………………………………………….26 
2.3.3. Biofilm inhibition………………………………………………………..32 
2.4. High throughput screening.............................................................................34 
3. Aims of the study......................................................................................................38 
4. Materials and methods.............................................................................................39 
4.1. Bacterial strains and growth conditions........................................................39 
4.2. Compound libraries and their screening for LsrK inhibition....................39 
4.3. LsrK assay selection.........................................................................................40 
4.3.1. Kinase-Glo Max Kinase Luminescence assay………………………..41 
4.3.2. ADP-Quest………………………………………………………………41 
4.4. LsrK inhibition assay.......................................................................................41 
4.5. Glycerol kinase inhibition assay....................................................................41 
4.6. Thermal shift assay..........................................................................................42 
4.7. AI-2 mediated QS interference assay based on β-galactosidase activity.42 
4.8. Luminescence-based AI-2 mediated QS interference assay......................43 
4.8.1. Plasmid construction…………………………………………………...43 
4.8.2. Assay development and screening campaign……………………….43 
4.9. Data analysis....................................................................................................44 
5. Results and discussion............................................................................................46 
5.1. Target-based screening...................................................................................46 
6 
 
5.1.1. LsrK assay development………………………………………………..46 
5.1.2. Screening campaigns……………………………………………………48 
5.2. Cell-based assay development and screening..............................................52 
5.2.1. Development of a bioreporter strain for QS inhibition studies…….52 
5.2.2. Screening campaign…………………………………………………….53 
6. Conclusions...............................................................................................................55 
7. References.................................................................................................................57 
























The failure of current antibiotics to address the spread of bacterial resistance 
has highlighted the need of new antimicrobial agents which would apply 
less selective pressure. To answer that, great interest has arisen towards 
antivirulence agents, compounds which target virulence factors and thus 
bacterial pathogenicity. As no link occurs between growth and virulence, 
antivirulence agents are considered less prone to promote resistance 
development.  
Due to its role as regulator in the establishment of infections, quorum 
sensing (QS), a communication strategy among bacteria mediated by the 
trafficking of small molecules called autoinducers (AI), has been widely 
investigated for the development of QS inhibitors with the aim of limiting 
bacterial virulence.  
This study aimed to develop new assays for the discovery of inhibitors 
targeting LsrK, a key kinase for autoinducer 2 (AI-2) mediated QS 
establishment in enteric bacteria. LsrK in fact phosphorylates the AI-2 
which, only in the phosphorylated form, can bind to the LsrR repressor and 
enhance the response to QS signals via activation of the lsr operon. A target-
based assay based on the detection of remaining ATP after the LsrK-
catalyzed reaction, was developed and utilized for screening of three 
different compound libraries. The libraries were chosen according to 
different criteria to increase the probability of finding LsrK inhibitors. 
Specifically in study I, the MicroSource Spectrum library was chosen due to 
its chemical diversity, in study II a collection of compounds was selected by 
virtual screening using a 3D LsrK model and in study III a small set of DPD 
analogues designed to target the LsrK substrate binding pocket was 
screened. The best hits from the three campaigns were harpagoside and 
rosolic acid, discovered by screening the MicroSource library. These 
compounds were also active in cell-based AI-2 mediated QS assay. 
However, the positive hits derived by study II and III provided interesting 
information about the catalytic site of LsrK. SAR studies in fact 
demonstrated that the best hits interact with Tyr 285 which may thus play a 
key role in the enzymatic activity.  
To facilitate the confirmation of hits selected by target-based assay and to 
offer a new tool for the rapid identification of QS inhibitors, in study IV a 
new bioreporter strain was created. This bioreporter emits luminescence as 
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response to AI-2 mediated QS activation. The assay has an easy set-up, 
requires only addition steps and is thus easily automatable. Additionally, 
the use of a mutant strain with reduced efflux activity allows enhanced 
intracellular accumulation of tested compounds increasing the chance to 
select active molecules to be used as scaffold for further development. The 
assay was used to test a set of 91 compounds selected to target the ATP 
binding site of LsrK. The same set of compounds was also tested in the 
target-based LsrK inhibition assay and the results were merged to lead to a 
final list of 24 potential QS inhibitors. Among those, 6 showed activity also 
against LsrK, which suggests that they decrease response to QS by inhibiting 
the kinase whereas 18 showed activity only on the cell-based assay implying 
that they target other components of the pathway. Further investigations are 
needed to define their mode of action.  
The inhibitors we found represent the first LsrK inhibitors and although 
their IC50 values limit follow-up studies and clinical applications, they 
increased our knowledge on LsrK and are useful scaffolds to better 
understand the enzyme-substrate interactions and to design compounds 
with improved properties. Furthermore, the AI-2 mediated QS interference 
assay represents an additional tool for the identification of QS inhibitors as it 
not only complements target-based assay but also allows to find new classes 
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ADP       adenosine diphosphate 
AHL       acyl homoserine lactone 
AI           autoinducer 
AI-2        autoinducer-2 
AI-3        autoinducer-3 
AIP         autoinducing peptide 
AMP      antimicrobial peptide 
ATCC    American Type Culture Collection 
ATP        adenosine triphosphate 
BSA         bovine serum albumin  
cIAIs       Complicated intra-abdominal infections 
cUTIs      Complicated urinary tract infections 
DMSO    dimethyl sulfoxide 
DSF         cis-11-methyl-2-dodecenoic acid 
DPD        (S)-4,5-dihydroxy-2,3-pentanedione 
ECM        extracellular matrix 
EMA        European Medicines Agency 
EPS          exopolysaccharides 
ESBLs       extended-spectrum β-lactamases 
ESKAPE  Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,  
                 Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
spp. 
FDA         Food and Drug Administration 
FIMM      Institute for Molecular Medicine Finland 
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FRET       fluorescence resonance energy transfer 
HAV       hospital acquired pneumoniae 
HHQ       2-heptyl-4-hydroxyquinoline 
HTS         high throughput screening 
IPTG        isopropyl β-D-1-thiogalactopyranoside 
LB            lysogenic broth 
mAB        monoclonal antibody 
MDROs   multidrug resistant organisms 
MRSA      methicillin resistant S. aureus 
MTAN    methylthioadenosine/S-adenosylhomocysteine nucleosidase 
NIG         National Institute of Genetic 
ONPG     2-nitrophenyl β-D-galactopyranoside  
PAβN      phe-arg-β-naphtylamide dihydrochloride 
PCR         polymerase chain reaction 
PDR         pan-resistant organisms  
PQI           2-heptyl-3-hydroxy-4(1H)-quinolone 
QS            quorum sensing 
PTS          phosphoenolpyruvate phosphotransferase system 
RT            room temperature 
TEA         triethanolamine  
TLC         thin layer chromatography 
UPEC      uropathogenic E. coli 
VAP        ventilated acquired pneumoniae 
XDR        extensively resistant organisms 









Antibiotics are considered as one of the most significant innovations in the 
history of medicine as they have improved and saved millions of lives 
throughout the years.  
The research for compounds with antibacterial properties dates back to the 
early 1900s, when, with the discovery of the first anti-syphilis drug, Paul 
Ehrlich marked the beginning of the “modern era” of antibiotics. Ehrlich’s 
approach included the systematic screening of hundreds of synthetic 
compounds on syphilis affected rabbits and it became an important 
milestone for drug discovery in pharmaceutical research [1]. 
Subsequently, with the discovery of penicillin by Fleming, the interest 
towards synthetic chemistry decreased in favor of natural products which 
were exploited as preferential source of effective and chemically diverse 
compounds. Most of the classes of antibiotics actually in use were 
discovered and characterized in those days, between the 1940s and 1960s, 
which are known as “golden era” of antibiotics. Only in the 1970s there was 
a return to synthetic approach to further optimize the compounds already 
available [1] and no new class of antibiotics was introduced till 2000 with the 
discovery of linezolid [2]. 
The lack of advancement in antibiotic discovery together with the misuse of 
antibiotics, with self-prescription and with the natural genetic variability of 
bacteria, has significantly reduced the effectiveness of available treatments 
[3, 4]. The term multidrug resistant organism (MDR) has been introduced to 
categorize bacteria which are resistant to many of the current antibiotics and 
becoming a threat to human health [5]. Among those, Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter spp., better known as the 
”ESKAPE” panel from their initials, are particularly relevant as they are 
considered critical threats to human life thanks to their ability to escape the 
action of several antibiotics [5, 6, 7].  
According to the World Health Organization (WHO), humanity is 
approaching a post-antibiotic phase when common infections will be deadly 
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for millions of people [8]. Although it may sound excessively alarmistic, this 
perspective is highlighting the need of a common effort to discover new 
antibiotics together with more sophisticated diagnosis methods, smarter 
delivery systems and new approaches to limit and prevent the spread of 
resistance. 
Aiming to remark the importance of a multidisciplinary and innovative 
approach to fight bacterial infections, the following review provides an 
overview on alternative strategies which are currently been investigated to 
control bacterial infections.    
 
2. Review of literature 
 
2.1. Resistance to antibiotics  
 
Traditional antibiotics target vital bacterial processes causing bacterial death 
(bactericidal effect) or preventing bacterial growth (bacteriostatic effect). 
Interfering with life functions has posed a strong selective pressure which, 
coupled with the spontaneous tendency of bacteria to mutate, has caused the 
spread of several resistant strains which are not susceptible to the currently 
available treatments. 
Resistance can be defined as the ability of bacteria to grow in the presence of 
normally cytotoxic concentration of antibiotic. Consequently, the resistant 
strain will get competitive advantage over the other cells becoming the 
dominant population. Bacteria can acquire resistance through mutations or 
transfer of genetic material which prevent the interaction of the antibiotic 
with its target. Additionally, chemical modifications can occur on the 
antibiotics, leading to the loss of the active motif. The most famous example 
is the hydrolysis of β-lactam ring catalyzed by β-lactamases which causes the 
degradation of penicillins, cephalosporine and carbapemenes [9]. The 
development of analogues of β-lactams in the following years have been 
coupled with the evolution of extended-spectrum β-lactamases (ESBls) and 
carbapemenases which have been transferred among bacteria via horizontal 
gene transfer with serious consequences for the treatment of infections. 
Other known chemical modifications include the acetylation, adenylation or 
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phosphorylation of the hydroxyl and amino-group in aminoglycosides with 
decrease of bacterial susceptibility to this class of antibiotics [10, 11].  
Target modifications may reduce the accessibility of the target or modify its 
structures. Binding of aminoglycosides to their ribosomal targets can be 
prevented by RNA methylation. Clinically relevant strains have also 
developed proteins which compete with antibiotics for the binding to the 
target [12]. Tet proteins bind to ribosomes and displace tetracycline by 
mimicking the activity of elongation factors during protein synthesis [13, 
14]. The quinolone resistance protein Qnr can mimic DNA and compete with 
fluoroquinolones for the binding to DNA gyrase and topoisomerase IV [15]. 
Although the mechanism is more complex as it affects enzymes that are vital 
for bacteria, mutations in the DNA gyrase and topoisomerase IV can also 
occur and contribute to resistance to fluoroquinolones by altering the 
binding pocket. Mutations in the gene encoding for the RNA polymerase 
cause amino acidic substitutions which prevents the binding of rifamycin 
whereas the regular enzymatic activity is conserved [16].    
In addition to acquired resistance, bacteria can also be intrinsically resistant 
to antibiotics i.e. resistance is due to structural characteristics. The outer 
membrane of Gram-negative bacteria is an excellent resistance mechanism 
as it makes them resistant to several antibiotics that are active against Gram-
positives and it also represents the main obstacle for the discovery of active 
molecules [17]. By regulating the expression of channels on the membrane, 
bacteria can also modulate their permeability. The downregulation of porins, 
is very often coupled with the overexpression of efflux pumps which 
actively expel xenobiotics out of the cell [18]. Mutations on the main 
regulators of the efflux pump system may affect the expression and the 
activity of the pumps. The exchange of genetic material encoding for the 
efflux pumps among bacteria provides them with a significantly complex 
and diverse efflux pump network [19,20,21,22]. 
The coexistence and synergism of the various resistance mechanisms led to 
the evolution of strains which are classified as MDR, XDR and PDR, 
according to the number of antimicrobials they can escape. MDR are strains 
resistant to at least 1 antibiotic from 3 or more antimicrobial classes whereas 
bacteria resistant to all the available treatments are defined pan-resistant 
organisms (PDR). An intermediate category has also been introduced to 
classify those organisms which are only susceptible to one or two categories 
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of antibiotics. Those are defined as extremely or extensively drug resistant 
bacteria (XDR) [23]. 
 
2.2. MDR and XDR pathogens: current treatments and new 
perspectives 
 
Few options are currently available for the treatment of MDR and XDR 
Gram-negatives which are one of the principal causes of death among 
hospitalized but also healthy individuals [24]. Among those colistin and 
fosfomycin are considered as the last frontier treatments when no other 
options are available. Colistin is a cyclic heptapeptide linked to a fatty acid 
chain produced by Bacillus polymyxa var. colistinus and active against aerobic 
Gram-negative bacteria [25, 26] It promotes cell damage by altering bacterial 
cell membrane permeability after binding to lipid A, a bacterial membrane 
component [27]. Due to the required high dosages and the high frequency of 
resistance and mutants, the use of monotherapy is controversial and the 
simultaneous administration of colistin with other antimicrobial agents is 
preferred to increase effectiveness and reduce the side effects [25, 28]. 
Combinations of colistin with carbapenem, fosfomycin, rifampin have 
shown improved efficacy for the treatment of problematic strains compared 
to treatment with single compounds [29, 30, 31]. Emergence of mutants is 
also generally less frequent. For colistin-resistant strains, fosfomycin, a 
bactericidal agent produced by several strains of Streptomyces, can be 
administrated [32]. Fosfomycin inhibits peptidoglycan synthesis and thus 
prevents the formation of bacterial cell wall with consequent cell damage 
[33]. It shows good penetration into tissues associated with low side effects 
[34]. However, combination therapy is advised to reduce resistance 
occurrence although an ideal drug to be co-administrated with fosfomycin 
has not yet been identified [35, 36, 37].  
Ultimately, aminoglycosides have also been used for the treatment of XDR, 
especially in combination with other classes of antibiotics with promising 
results [38, 39]. Limitation is represented by different susceptibility of 
bacteria due to the expression of different classes of aminoglycosides 
modifying enzymes and also the need of surveillance for the administrated 
doses in order to avoid toxicity [40]. 
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In the current scenario of available antibiotics, the key element seems to be 
combination as the simultaneous administration of a known antibiotics with 
a new agent restoring bacterial susceptibility has been proven to be highly 
effective against critical strains. 
As proof of concept for the effectiveness of combination therapy for the 
treatment of MDR and XDR, among the few new treatments recently 
approved by Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) (Table 1), three of them are combinations of a 
traditionally used antibiotic complemented by an ESBLs inhibitor. The 
activity of ceftazidime, ceftolozone and meropenem is in fact restored in 
presence of avibactam, tazobactam and vaborbactam, respectively [41, 42, 
43]. 
Additionally, plazomycin, a new generation aminoglycoside, was approved 
for the treatment of Enterobacteriaceae. The ability to enter lungs makes it also 
a candidate for the treatment of ventilated associated pneumoniae (VAP) in 
combination with β-lactamase inhibitors. Eravacycline is a synthetic 
fluorocycline active against Gram-negative bacilli and Gram-positive cocci 
with limited side effects.  
 
Table 1: List of approved drugs for the treatment of Gram-negative 
infections between 2014 and 2019 [44] 
                                               
1 Complicated urinary tract infections 
2 Complicated intra-abdominal infections 
3 Hospital acquired pneumonia 
4 Ventilated associated pneumonia 
5 Acute pyelonephritis 
Drug Class Status  
Ceftazidime/avibactam 
combination of avibactam, a β-
lactamase inhibitor, with 
ceftazidime 
- approved by FDA  and EMA  for the 
treatment of cUTI1, cIAI2, HAP3, and 
VAP4 
- approved by EMA for the 
treatment of infections by aerobic 
Gram-negative 
when limited options are available 
Ceftolozane/ 
Tazobactam 
combination of tazobactam, a 
β-lactamase inhibitor, with 
ceftolozane 
 
- approved by FDA and EMA for the 
treatment of cIAI (in combination 




combination of vaborbactam, a 
β-lactamase inhibitor, with 
meropenem 
- approved by FDA for the treatment 
of cUTI, including AP 
- approved by EMA for the 
treatment of cUTI, cIAI, VAP, HAP, 




The above options are still meant to be used in combination with colistin or 
fosfomycin for the treatment of severe infections. In particular 
ceftazimide/avibactam and meropenem/vaborbactam are indicated for the 
treatment of CRE infections whereas cefozolane/tazobactam is indicated for 
the treatment of MDR P. aeruginosa. 
 
2.3. Antivirulence strategies 
 
Colistin, fosfomycin and the new combination therapies, despite their 
potential for the treatment of XDR and MDR, cannot fulfill the need of new 
antibiotics, especially when considering that they are bactericidal and, 
consequently, will apply a strong pressure for the selection of mutants. 
Surveillance and consciousness in the use of those antibiotics is thus 
fundamental to save more human lives, offering at the same time a time 
window to scientists for the discovery of alternative approaches which may 
reduce the selective pressure. As big pharma companies exited the field of 
antimicrobials due to low profit margins, several institutions, including 
small companies and academic groups, have in fact contributed to the 
development of new antimicrobial strategies which may translate into clinic 
in the coming years. According to a recent review published in Nature 
Review Microbiology, 407 projects are on-going to discover new treatments 
against bacteria. Among those, 46% still focuses on compounds with 
antibacterial properties, including either derivatives of traditional antibiotics 
or new targets, whereas the 56% is looking at new strategies spanning from 
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Plazomycin semisynthetic aminoglycoside 
- approved by FDA for the treatment 
of  cUTI, including AP 
Eravacycline synthetic fluorocycline 
- approved by FDA and EMA for the 
















Figure 1: Areas of research for new antimicrobials [45]. 
 
A portion of new innovations is reserved to the development of 
antivirulence agents which target virulence factors, responsible for bacterial 
pathogenicity. This approach aims to make bacteria inoffensive so that they 
can be naturally cleared by the host immune system [46, 47, 48]. The 
advantage of antivirulence therapy is primarily the low selective pressure. In 
fact, since antivirulence agents do not have an impact on growth, the 
treatment is considered less prone to promote resistance.  
A second benefit is specificity. Many virulence factors are species specific or 
limited to a restricted number of strains, and thus do not impair endogenous 
bacteria which normally do not possess virulence factors. Additionally, 
specificity also lowers the risk of resistance as the horizontal transfer of 
mutated genes is unlikely to happen [49, 50]. On the other hand, it limits the 
applicability of antivirulence drugs quite significantly as each patient may 
carry a different strain with different mutations so that data derived from 
clinical trials and surveillance studies are hard to interpret due to the high 
variability. The lack of an agreement about final read-outs to monitor effects 
also impacts the advancement of antivirulence drugs towards clinical trials. 
In fact, whereas for traditional antibiotics a therapy is successful when the  
Antibacterial preclinical pipeline: 407 projects 
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bacterial cells are dead, for antivirulence agents cell death is an undesired 
effect and multiple parameters should be analyzed such as reduced gravity 
of the infection or level of the immune response [51]. 
However, the interest of the scientific community towards antivirulence 
agents is considerably high. The most interesting aspect of antivirulence 
therapies is the number and variety of targets. In fact, host colonization, 
motility, toxin production and release, and biofilm formation are all 
contributing to virulence and each of them is a complex process which 
involves several proteins, potentially suitable as targets to disrupt 
pathogenicity. 
To initiate the infection, pathogens need to adhere and colonize the host 
tissue. Bacterial adhesion apparatus generally includes a protruding 
structure associated with adhesins, proteins responsible for the recognition 
and binding to the host tissue. FimH mediates the adhesion of 
uropathogenic E. coli (UPEC) to the uroepithelium by binding to 
mannosylated components. Thus mannosides have the potential to prevent 
UPEC adhesion to the bladder cells by binding FimH [52]. UPEC also 
colonizes kidneys by using Fim1H which binds to β-2-galactoside. N-acetyl 
galactosamine inhibits the binding and ensures full recovery of infected mice 
when administrated in combination with mannosides [53]. Enterobacteriaceae 
can translocate the intimin receptor Tir to the host cell via the type III 
translocation system and interact with it by intimin protein forming stable 
interactions which support colonization and damage [54]. The treatment 
with peptides which interfere with the correct transporter assembly have 
successfully prevented lesions formation in murine model [55]. 
Toxins are small proteins secreted by bacteria to damage the host and impair 
its metabolic pathways [56]. The functionality of toxins requires the 
interaction with a host receptor activating lethal pathways for the cells. S. 
aureus produces a variety of toxins which are responsible for its 
pathogenicity. -hemolysin kills blood and immune cells by disrupting their 
cellular membranes [57]. Treatment with monoclonal antibodies 
significantly reduces the effect of toxins and cures the infections. MED14893 
mAB inhibits -hemolysin oligomerization and its interaction with the 
receptor reducing bacteremia and lesions due to S. aureus in mice [58]. A 
mice model of lung co-infection of S. aureus and Gram-negative bacteria 
regained health after preimmunization with an antitoxinA mAB [59]. 
Liposomes containing high percentage of cholesterol and sphingomyelin 
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were able to capture toxins based on their affinity for cholesterol with a 
positive effect on animals infected with S. pneumoniae and S. aureus [60]. 
TcdA and TcdB toxins, from C. difficile, cause cell damage and spreading of 
bacteria by interacting with the Ras superfamily of small GTPases. Different 
conformations of TcdB have been isolated and correspond to different level 
of virulence [61]. The sequence of the high virulence variant of TcdB was 
used to design peptide which could destabilize the protein and reduce its 
activity [62]. 
The type III translocation system is used by Gram-negative bacteria to inject 
toxins into the host cell. Several compounds have been proposed to prevent 
the assembly of the transporter and mAB targeting the PcrV, protein 
associated to the needle, have entered clinical trials for the treatment of P. 
aeruginosa infections [63]. 
Despite identifying toxins and clarifying their mechanism of action may be 
difficult and dispendious, anti-toxin treatments were the first antivirulence 
agents approved by FDA but many others are under investigations (Table 2). 
BabyBIG and BAT were approved in 2003 and 2013, respectively, for the 
treatment of C. botulinum infections [64, 65]. C. botulinum secretes BoNT, a 
neurotoxin causing paralysis by impairing neuromuscular junctions. 
BabyBIG is an immunoglobulin derived by human donors immunized with 
BoNT (type A-E) used for the treatment of infant botulism whereas BAT 
derives from immunization of horses and has a wider spectrum targeting 
also BoNT type H.  Raxibacumab [66] and obiltoxaximab [67] were approved 
for the treatment of B. antracis infections. Both mAbs target the protective 
antigen (PA) and prevent the PA mediated-internalization of the lethal 
factor and oedema factor, toxins causing the anthrax infections. 
Bezlotoxumab, approved in 2016 for the treatment of C. difficile infections 
[68], targets TcdB, an exotoxin which, together with TcdA, causes C. difficile 




Table 2: Antivirulence agents at different stages of drug development in 
2017 [69] 
a) Approved drugs 













































TcdB FDA approved 
 
b) Potential drugs in clinical trials 




MEDI4893 Human, mAb IgG1 
Staphylococcus 
aureus 
α-Toxin Phase II 
AR-301 Human, mAb IgG1 
Staphylococcus 
aureus 
α-Toxin Phase II 
ASN-100 (a combination 
of ASN-1 and ASN-2) 















Psl and PcrV Phase I and II 










                                               
6 Fragment antigen-binding 











11D and 4C 
Chimpanzee, mAbs 
IgG1 and IgG3 





F26G3, F24F2 and 
F26G4 




























































































































































































Mouse, mAbs IgG1 
and IgG2a 
Enterobacter spp. Stx1e Preclinical 
































2.3.2. Quorum sensing inhibition 
 
As virulence is the result of the synergism of multiple virulence factors, 
disrupting virulence regulatory system may offer a unique opportunity to 
disarm bacteria by targeting several virulence factors simultaneously. For 
this purpose, quorum sensing (QS) has raised a great interest in the past 
years. In fact, this network, which relies on release and recognition of small 
molecules called autoinducers (AI), has been proposed as regulator of 
several bacterial group behaviors such as host colonization and 
pathogenicity [70, 71].  
The discovery that bacteria can communicate dates to the 70s when LuxI and 
LuxR were proven to be regulators of luminescence in V. fischeri [72, 73]. 
Later homologous genes were identified in other species together with 
numerous autoinducer classes (Table 3). 
 
Table 3: Examples of autoinducers and their spectrum of activity {74} 
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Acyl homoserine lactone (AHL), the most known autoinducer in Gram-
negatives, is characterized by a lactone ring connected to an acyl chain with 
various length, oxidation and saturation. Synthases from the Lux1 family 
catalyze AHL synthesis starting from the S-adenosylmethionine [75]. The 
signal moves to the extracellular environment where, after exceeding a 
certain threshold, binds to LuxR receptor with an impact on gene 
expression. 
Gram-positive bacteria secrete oligopeptides as QS mediators. Oligopeptides 
are released into the extracellular environment where they undergo 
structural modification before interacting with the cognate receptor on 
bacterial membrane [76]. The binding initiates a phosphorylation cascade 
which ends with the de-repression of QS responsive genes. In S. aureus the 
autoinducing peptide (AIP) controls the accessory gene regulator system 
(agr). The agr system contains two gene clusters: RNAII and RNAIII. RNAIII 
includes QS responsive genes whereas RNAII encodes for AgrB, AgrC, 
AgrD and AgrA, involved in production and processing of the AIP. AIP 
derives from AgrD, a precursor peptide which is processed by AgrB, a 
transmembrane peptidase, and SspB, a type 1 signal peptidase. Once it is 
released extracellularly, AIP binds to the receptor AgrC starting a 
phosphorylation cascade which ends with the binding of the 
phosphorylated AgrA to the P2 and P3, two promoters which regulate the 

















Figure 2: Schematization of agr mediated QS system in S. aureus. 
AI-2 is used as QS mediator by both classes of bacteria for interspecies and 
intraspecies communication. Methylthioadenosine/S-adenosylhomocysteine 
nucleosidase (MTAN) and the metalloenzyme LuxS synthetize 4,5-
dihydroxy-2,3-pentanedione (DPD), a highly unstable molecule which exists 
as balance of several cyclic forms [78]. Whereas AI-2 synthetic pathway 
seems to be highly conserved, AI-2 processing may vary considerably. As 
general mechanism AI-2 is extruded and binds to a receptor after a certain 
concentration is reached. According to current knowledge, two classes of 
receptors have been well described. In V. harveyi, AI-2 interacts with LuxP, a 
periplasmatic protein which modulates the activity of the kinase LuxQ. At 
low cell density the complex LuxPQ phosphorylates the downstream 
proteins LuxU and LuxO which, in the phosphorylated form, promote the 
transcription of regulatory sRNAs, named Qrr, with the consequent 
inhibition of LuxR, a regulator of high cellular density behavior [79, 80]. 
When the furanosyl borate diester form of AI-2 binds to the receptor, the 
complex acts as phosphatase with consequent dephosphorylation of LuxO, 
inhibition of the sRNAs transcription and LuxR expression and activity 



















Figure 3: Schematization of AI-2 mediated QS in V. harveyi: a) at low cell-
density; b) at high cell-density. 
 
In enteric bacteria, LsrB-like receptors recognize the signal which is 
internalized by a transporter formed by two transmembrane proteins, LsrC 
and LsrD, linked to a third protein, LsrA, with ATPase activity. The receptor 
and the transporter’s components are encoded by lsrACDBFGE operon 
which also encodes for LsrG and LsrE, responsible for AI-2 degradation. 
LsrK, and LsrR, which respectively encode for a kinase and a repressor, are 
located adjacently to the operon and are transcribed divergently. Inside the 
cell, LsrK phosphorylates the signal molecule which only in the 
phosphorylated form can bind and inactivate AI-2 repressor LsrR, 
enhancing the transcription of the lsr operon and promoting the response to 
QS [82]. The LsrB-like receptor mediated pathway is under control of the 
phosphoenolpyruvate phosphotransferase system (PTS) which may mediate 
the initial internalization of the AI-2 to initiate the basal expression of the 
operon. In fact it has been shown that mutants lacking EI and EIIAglc, 
members of the PTS system, are unable to correctly internalize and process 
AI-2. This phenomenon could be explained by the involvement of the PTS 
system in the internalization of an initial amount of AI-2 which mediates the 
activation of the lsr operon. Although the whole mechanism remains 
unknown, the role of PTS in the AI-2 mediated QS is not surprising as it 
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normally mediates internalization of carbohydrates and thus reflects the 









Figure 4: Schematization of AI-2 mediated QS pathway in enteric bacteria. 
Additional autoinducers are 2-heptyl-4-hydroxyquinoline (HHQ) and 2-
heptyl-3-hydroxy-4(1H)-quinolone (PQI), in P. aeruginosa [84], cis-11-methyl-
2-dodecenoic acid (DSF), active in several strains as c-di-GMP level 
modulator [85], and autoinducer (AI-3) isolated from E. coli O157:H7. 
Besides promoting host colonization and damaging, AI-3 can stimulate 
virulence by cross-signaling with eukaryotic hormones, epinephrine and 
norepinephrine. QseC, a bacterial membrane bound histidine kinase sensor 
present in many human and plant pathogens, act as bacterial receptor by 
binding the hormone-like signal molecule AI-3, but, at the same time, it also 
acts like adrenergic receptor by interacting with epinephrine and 
norepinephrine [86].  
QS pathways are highly interconnected. In fact, bacteria can respond to 
different signals and adjust their behavior in response to the combination of 
the autoinducers that they sense. The mechanism may have been evolved to 
detect not only the number of bacteria but also the composition of the 
population and tailor a response accordingly [87, 88]. Vibrio and Pseudomonas 
are perfect examples of an integrated response to several autoinducers. In 
fact, in Vibrio, the binding of CAI-2 and 3OH4CHSL to CsqS and LuxN 
receptors, respectively, activates the same phosphorylation cascade initiated 
by AI-2.  
In Pseudomonas, 4 different mechanisms have been identified. LasIR and 
RhrIR recognize 3OC12HSL and C4HSL respectively. The binding of 
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3OC12HSL to LasR enhances AHL QS response by potentiating the 
expression of both receptors whereas the binding of C4HSL to RhIR only 
increase RhIR expression without affecting LasIR. Additionally, Pseudomonas 
also responds to PQS and IQS. Las has been proposed as one general QS 
regulator. It is activated by 3OC12HSL and promotes the transcription of the 
RhIR system among other virulence factors. At the same time C4HSL binds 
to RhiR promoting its own transcription. Both signals affect PQS as las 
promotes pqs operon transcription whereas RhiR inhibits it. Thus, the 
pathway is controlled by the ratio between the two autoinducers. However, 
both systems affect the PQS mediated QS. PQS promotes its own production 
and RhrIR activity which downregulate PQS itself. Additionally, a QscR 
protein which sequestrates 3OC12HSL has also been identified as AHL-
mediated QS modulator [89].  
Inhibiting the synthetic pathway of an autoinducer may cause QS 
inactivation. However, as it usually is a cytoplasmatic event, molecules able 
to pass the bacterial membrane are needed. Enzymatic degradation of 
autoinducers has been preferred as it targets their extracellular form. 
Lactonases and acylases catalyze AHL degradation. Lactonases break the 
lactone ring by targeting the ester bond [90]. Acylases act on the acyl chain 
by breaking the amine bond which connect them to the ring [91]. 
Oxidoreductases prevent the recognition of the autoinducer by its cognate 
receptor by altering the side chain’s oxidation state [92]. All those classes of 
enzymes have been effective against pathogenic bacteria by restoring their 
susceptibility to regular antibiotics, preventing biofilm formation and spread 
of infections. Unfortunately, their instability limits their applications in vivo. 
Monoclonal antibodies targeting QS have also been developed. RS2-1G9 and 
XYD-11G2, both inhibiting AHL activity, blocked inflammation and 
pyocyanin production in an in vivo model of infection [93, 94]. 
Vaccines based on an autoinducer conjugated to a vehicle have also proven 
to be a valid approach. In fact immunization with a viral particle based on 
the bacteriophage protein PP7 including a sequence from the autoinducer 
peptide 1 from S. aureus significantly reduced mortality in animal models 
[95]. 3-oxo-dodecanoyl homoserine lactone conjugated with BSA generated 
an antibody response in mice and protected them from Pseudomonas lung 
infection [96].  
Natural and synthetic compounds have been proposed as candidates for the 
development of a class of antivirulence agents based on the inhibition of the 
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autoinducer/receptor interactions. 6-gingerol, isolated from Zingiber 
officinale, binds to LsrR and inhibits transcription of QS related genes, 
production of virulence factors and formation of biofilm, reducing severity 
of the infection in mice infected with P. aeruginosa [97]. Naringenin, a 
flavonoid extracted from fruits, modulates α-hemolysin mediated damages 
in a mouse model of MRSA infection by reducing AgrA levels, which 
promotes the expression of the agr operon involved in QS in S. aureus [98].   
Genetic engineering may also contribute to the development of innovative 
quorum quenching approaches. E. coli Nissle has been engineered to 
promote its own distruction when detecting 3-oxo-C12 HSL produced by P. 
aeruginosa with release of DNAses and bacteriocins with antimicrobial 
activity [99]. Releasing bacteria with abnormal QS expression created by 
Clustered Regularly Interspaced Short Palindromic Repeats-Cas 9 
interference (CRISPRi) technology into the environment to spread the 
construct via horizontal gene transfer and to impair the QS system in regular 
strains has been proposed [100]. Although this technology presents several 
consequences due to the release of genetically modified organisms in the 
environment and it is far away from being an immediate solution for the 
treatment of bacteria, it may represent a completely new approach were a 
mechanism, such as horizontal gene transfer, that bacteria use to escape 
antibiotics become the new tool to clear them.  
 
2.3.3. Biofilm inhibition 
 
Biofilm is a bacterial community surrounded by an extracellular matrix 
(ECM) containing exopolysaccharides (EPS), proteins and nucleic acids. 
Physical forces and adhesion proteins mediate bacterial attachment to a 
surface and initiate the organization of aggregates which will build the first 
layer of biofilm [101, 102]. The adhesion is followed by a maturation phase 
with the production of the ECM components which supports the formation 
of a complex 3D structures. Ultimately, the biofilm will be disrupted causing 
the spreading of bacteria and propagation of the infection.  
As biofilm forming community, bacteria obtain several advantages. Among 
those, resistance to antibiotics is particularly significant as it makes biofilm 
hard to eradicate and thus a serious complication for the complete clearance 
of infection. Resistance is a multifactorial phenomenon partially due to the 
different metabolic activity of biofilm embedded cells compared to the 
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planktonic status [103]. Within biofilm, growth is not a priority for bacteria 
which significantly suppress their metabolic activity. As antibiotics target 
vital processes in bacteria linked to their duplication, dormant cells become 
immune to the treatment and may eventually reactivate in absence of the 
antibiotic, becoming pathogenic [104, 105, 106, 107]. ECM is also essential for 
resistance as it actively hinders antibiotics penetration and support 
horizontal gene transfer with consequent spreading of resistance [108]. 
The role of biofilm in infection has been underestimated for many years. 
Persistent cells cause chronicity of infections which can be fatal, especially 
for immunocompromised patients [109]. The advancement in implant 
design and application also increased the spread of biofilm-related infections 
as it provides an additional surface suitable for contamination [110]. Thus, 
preventing biofilm formation or promoting its dispersal should become an 
integral part of the infection treatment.  
Albeit QS has been recognized as one of the main biofilm regulators and its 
inhibition may also be associated, among the other effects, to biofilm 
reduction, specific biofilm regulators have also been discovered and 
targeted.  
C-di-GMP and pppGDPpp are GTP derivatives which contribute to biofilm 
formation in several bacteria [111]. pppGDPpp acts as transcriptional factor 
for genes involved in biofilm formation and development of persistent cells 
[112]. C-di-GMP controls biofilm initiation by downregulating mobility and 
upregulating mechanism of adhesion and production of ECM [113]. 
Hampering these two regulators could strongly affect biofilm and 
consequently restore bacterial susceptibility to regular antibiotics and host 
immune system. C-di-GMP is synthetized by diguanylate cyclase and 
degraded by phospohodiesterases[114]. Interfering with the c-di-GMP 
synthesis by inhibition of diguanylate cyclase has been shown to be active 
against in vitro biofilm formed by P. aeruginosa and Acinetobacter [115]. 
Promoting c-di-GMP degradation by overexpression of phosphodiesterases 
in P. aeruginosa reduced biofilm formation in a mouse model of implant 
related infection [116].  
Dispersal of preformed biofilm will expose bacterial cells to the action of 
antibiotics. Enzymes for the degradation of matrix components cause biofilm 
disruption in several models of biofilm and are particularly efficient when 
used in combination with antibiotics [117, 118, 119]. Antibiofilm molecules 
are also available in nature as organisms, including bacteria, have evolved 
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self-defense mechanisms to contrast biofilm formation by invasive species. 
Biofilm inhibitors have been identified in Vibrio and Pseudomonas [120, 121]. 
EPS273, isolated from P. stutzeri 273, prevents the formation of stable biofilm 
in Pseudomonas by altering the pyocyanin pathway [122]. Nitric oxide has 
been found active against biofilm in several strains [123]. Although the 
numerous side effects restrict its application in clinic, the administration of 
picomolar doses of nitric oxide have been proven to be safe and still efficient 
in biofilm eradication. Biofilm of P. aeruginosa has been cleared by a chimeric 
drug containing cephalosporine linked to a NO donor, released after 
cleavage of the β-lactam ring by β-lactamases, in vitro model [124]. The 
number of bacterial colonies in a chronic model of biofilm-related infection 
have been considerably reduced by effect of gallium. In fact, this metal is 
accumulated by bacteria due to its similarity to iron but, as it cannot replace 
iron functionality, leads to cell death [125]. 
Antibiotics traditionally used for the treatment of slow-growing species find 
their application in the treatment of biofilm related infection as they may 
target persisters. In fact antibiofilm agents have the potential to destabilize 
biofilm and thus restore susceptibility to antimicrobial compounds. A 
screening campaign aiming to evaluate the effect of small molecules, already 
approved as drugs, in combination with colistin for the treatment of P. 
aeruginosa led to the identification of two compounds, auranofin and 
clomiphene citrate, which together with colistin were active against the 
planktonic form and mature biofilm formed by laboratory and clinical strain 
[126]. Co-administration of a new class of D-enantiomeric antimicrobial 
peptide (AMP), acting as (p)ppGpp repressors, with ciprofloxacin, 
imipenem or trombomycin has improved the effectiveness of the antibiotic 
alone. Additionally, it contributed to successful eradication of mature 
biofilm formed by important pathogens such as K. pneumoniae, A. baumanii 
and S. enterica [127].  
 
2.4. High throughput screening 
 
High throughput screening (HTS) is a standardized procedure which allows 
rapid assessment of thousands of compounds for the identification of few 
candidates which are suitable for further development. A general workflow 
of a screening campaign includes the primary screening where compounds 
are typically screened in singlet or duplicate at one concentration followed 
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by a second round of screening (secondary screening) where the positive 
hits are confirmed and tested for dose response. Follow-up studies are then 
performed to further characterize the hits and confirm their activity to 
provide most potential compounds for further development [128]. 
A screening campaign starts with the assay development which consists of 
designing and validating a sensitive and simple assay suitable for 
automation. An ideal assay should only include addition and incubation 
steps before the read-out as those are easier to automate. 
The nature of the assays is strictly related to the biological phenomenon of 
interest. However, as general rule assays are divided into biochemical or 
cell-based assays. Biochemical assays are target-based assays, which monitor 
the interaction between a test compound and a target which is known to be 
relevant in a disease. Those assays have high throughput and are less time 
consuming. However, they are not always physiological and thus the hits 
may not be active when tested in cellular environment. 
Cell-based assays measure the effect of test compounds typically on an 
entire pathway in physiological conditions. The target is very often initially 
not known, and several studies are required to identify it and determine the 
mode of action. These kinds of assays are thus very suitable for the 
identification of new targets to be further investigated or new classes of 
drugs. However, the throughput is usually lower and they are more 
complex and time consuming than target-based assays [129].  
Additionally, virtual screening is also becoming more popular due to the 
advancements in technology. Indeed, it allows fast screening of large 
compound databases providing restricted numbers of hits to be tested in 
vitro. This approach includes target-based and structure-based virtual 
screening. The first option requires the available structure of the target 
which is used to screen virtual libraries; the structure-based procedure 
instead is based on the knowledge of bioactive compound(s) which are used 
as templates to identify analogues which share the same active motif [130]. 
Since the aim of a screening campaign is to select few active molecules out of 
large number of inactive compounds, quality control is critical. Assays for 
HTS must be carefully optimized and validated to ensure the robustness and 
reproducibility. Assay quality is typically assessed by so-called assay quality 
parameters calculated from controls. For example, signal-to-background 
(S/B) ratio is normally used to determine the separation between the 
36 
 
maximum and minimum controls. Z’ factor is a more useful parameter as it 
considers not only the mean of the controls but also the SD as indicator of 
the variability. The value is comprised between 0 and 1 with values ≤0.5 
indicating a poor-quality assay and values ≥ 0.5 indicating good quality 
[131]. 
Various detection technologies are used in HTS assays to quantify the effect 
of a compound on the target or pathway being studied. The selected 
technology may influence significantly the sensitivity of the assay. 
Fluorescence is based on an ability to emit the absorbed electromagnetic 
radiation. It is widely used in HTS although it is quite susceptible to 
interference e.g. from auto fluorescent compounds [132]. To reduce the 
disturbance, different approaches have been developed, for example, by 
aiming to monitor the proximity of two fluorescent probes rather than 
directly detecting fluorescence [133]. The fluorescence resonance energy 
transfer (FRET) is based on the interaction of an acceptor and donor 
molecule which are close in space. The donor emits at the wavelength which 
is absorbed by the acceptor. Thus, by exciting at the donor wavelength and 
reading at the acceptor emission wavelength, it is possible to determine the 
proximity of the two probes [134]. As evolution of FRET, time-resolved 
fluorescence (TRF) uses the same principle but with a donor which will have 
a longer fluorescence decay time than the interfering compounds [135].  
The term bioluminescence indicates the production of light as product of a 
chemical reaction catalyzed by enzymes named luciferases. Bacterial 
luciferase has two domains encoded respectively by luxA and luxB which 
are organized into the luxCDABEG operon. LuxC, LuxD and LuxE encode 
for an enzymatic complex responsible for the synthesis of an aliphatic 
aldehyde whereas luxG encodes for a flavin reductase. The long fatty acid 
aldehyde is oxidized by a reduced flavin mononucleotide with consequent 
production of light [136]. The eukaryotic reaction involves different 
substrates. The most common eukaryotic luciferase isolated from firefly 
catalyzes the conversion of luciferin into oxyluciferin in an ATP-dependent 
manner with production of light as a side product [137]. As it is an ATP 
dependent reaction, this method is particularly suitable for the study of 
kinases or cellular viability. The luciferase gene can be inserted into a 
plasmid under control of a promoter of interest and cloned into a host strain 
to generate a bioreporter strain. The emission of light will be proportional to 
the level of activation of the promoter after the treatment with a compound 
of interest [138].  
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Additionally, platforms like FRET have been developed also for 
luminescence. Alphascreen technology involves a donor or an acceptor 
molecule linked to beads. When the donor is excited at 680 nm it promotes 
the conversion of oxygen into singlet oxygen which can travel for 
approximately 200 nm before decaying. If the acceptor is within that 
distance the singlet oxygen initiates a chemiluminescent reaction on the 
acceptor which emits between 520 and 620 nm. In this case the interference 






3. Aims of the study 
 
Since QS has been highlighted as one of the main regulators of bacterial 
virulence, the inhibition of enzymes involved in QS establishment has 
become one of the most promising strategies to reduce bacterial 
pathogenicity. The aim of this thesis was the development of a screening 
approach for the discovery of LsrK inhibitors. LsrK has been described as 
one of the key enzymes in the AI-2-mediated QS in gut enteric bacteria. In 
fact, once DPD, the precursor of AI-2, is internalized by the Lsr transporter, 
it is phosphorylated by LsrK and only the phosphorylated form can bind the 
repressor LsrR, enhancing the response to QS signals. Additionally, it has 
been demonstrated that mutant bacteria which do not express LsrK, are 
unable to establish AI-2-mediated QS [140], qualifying the enzyme as 
potential target for the development of a new class of antivirulence agents. 
Specifically, the aims were: 
• design, evaluation, optimization and validation of HTS-compatible 
assay for screening chemical libraries to identify LsrK inhibitors (I) 
• screening of chemical libraries by the LsrK inhibition assay. Three 
chemical libraries were selected: a commercially available library, a 
small set of commercially available compounds selected by virtual 
screening and a small set of DPD analogues. (I, II, III) 
• follow-up studies of the hits selected by primary screening including 
IC50 estimation, binding assays, and cell-based assays (I, II, III) 
• development of a luminescence-based bioreporter strain to confirm 
the activity of positive hits selected by target-based assay as well as to 
allow fast and simple cell-based screening of chemical libraries to 





4. Materials and methods 
 
This section includes a summary of the materials and methods used in the 
studies. The detailed procedures can be found in the original publications (I-
IV).   
 
4.1. Bacterial strains and growth conditions 
 
For the over-expression of LsrK, E. coli strain MET1158 [E. coli, amp 
resistance, BL21 (DE3) luxS-, with pMET1144 (lsrK-His in pET21b)] was 
kindly donated by Prof. Karina Xavier (Instituto Gulbenkian de Ciencia, 
Portugal) [141]. The strain was grown in YTPG (yeast, tryptone, phosphate 
buffer and glucose) medium supplemented with 100 μg/ml ampicillin at 
18°C (250 rpm) until exponential phase and protein expression was induced 
by 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 9 h at 22°C 
(250 rpm). LsrK is purified by Ni-nitriloacetic acid chromatography. 
E. coli LW7 pLW11 and E. coli pBAC-LacZ, used in the AI-2 mediated QS 
interference assay, were kindly provided by Prof. William Bentley 
(University of Maryland, USA) and Keith Joung (Addgene plasmid # 13422), 
respectively. Both strains were grown at 37 °C in lysogenic broth (LB) 
supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin for E. coli 
LW7 pLW11, or with 12.5 µg/ml chloramphenicol for E. coli pBAC-LacZ. 
For study IV, E. coli JW5503 and E. coli ATCC 25922 were obtained from the 
NBRP-E. coli collection at the National Institute of Genetics (NIG, Japan) and 
the American Type Culture Collection (ATCC) via Microbiologics Inc. (St. 
Cloud, MN), respectively. E. coli JW5503 and E. coli ATCC 25922 were 
transformed with pET-Plsrlux and grown at 37 °C in LB supplemented with 
100 µg/ml kanamycin and 100 µg/ml ampicillin or with 100 µg/ml ampicillin 
respectively.  
 
4.2. Compound libraries and their screening for LsrK inhibition 
 
For study I, the MicroSource Spectrum library containing known drugs 
(50%), natural products (30%) and other bioactive compounds (20%) for a 
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total of 2000 compounds, was purchased from FIMM. The library was used 
for the assay validation. Compounds were pre-plated by Echo acoustic 
dispenser (Echo, Labcyte Inc., CA, USA) into 384-well plates at 50 µM 
concentration in singles. The set of 107 positive hits selected for secondary 
screening were obtained from FIMM and pre-plated at 10 µM in singles to 
be re-tested against LsrK and at 50 µM in singles to be tested against 
glycerol kinase. The 22 compounds which were selected by secondary 
screening for dose-response assay were pre-plated at FIMM at 6 
concentrations (25-0.39 µM). Finally, harpagoside, rosolic acid, agaric acid 
and aurin tricarboxylic acid were purchased from Sigma (USA) for further 
studies. 
For study II, a set of 104 compounds pre-selected by virtual screening was 
acquired from FIMM and pre-plated by an Echo acoustic dispenser in 384-
well plates in triplicate at 2 concentrations (20 and 200 µM) for the LsrK 
inhibition assay. The positive hits were used as template for the selection of 
analogues in the MolPort database by catalogue-search approach. The 
prioritized analogues were purchased from different vendors and tested at 
200 µM in the LsrK inhibition assay and the positive hits were selected for 
dose-response. 
In study III, two sets of DPD-inspired compounds including respectively 19 
and 29 compounds were synthetized by the Medicinal Chemistry 
department of Taros Chemicals GmbH&Co (Dortmund, Germany). 
Compounds were dissolved in DMSO and plated in triplicate at 200 µM in 
384-well plate. 
In study IV, a library of 91 compounds designed to target the ATP binding 
pocket of DNA-gyrase was synthetized and provided by the Medicinal 
Chemistry Department of the Faculty of Pharmacy at the University of 
Ljubljana (Ljubljana, Slovenia). Compounds were dissolved in DMSO and 
plated in 384-well plate in triplicate at a final concentration of 100 µM for the 
primary screening against LsrK. The same set was plated in triplicate in 96-
well plate at 100 µM for the bioreporter assay 
 
4.3. LsrK assay selection 
 
To develop a LsrK inhibition assay, two commercially available kit based on 




4.3.1. Kinase-Glo Max Kinase Luminescence assay 
 
300 nM LsrK and 300 µM DPD (Carbosynth, UK) in assay buffer [25 mM 
triethanolamine (TEA), 200 µM MgCl2, 0.1 mg/ml bovine serum albumin 
(BSA), 0.01 % Triton X-100] were added to a 384-well plate (Greiner). 100 µM 
ATP were added as last component to start the reaction. The total assay 
volume was 20 µl. The reaction was kept at RT for 15 minutes. According to 
manufacturer’s instruction, 20 μl of kit’s components were added to the 
plate. After 15 min, the luminescence was recorder at Varioskan LUX plate 
reader (Thermo Fisher Scientific, Finland) 
4.3.2. ADP-Quest 
 
300 nM LsrK, 300 µM DPD and 100 µM ATP in assay buffer [25 mM 
triethanolamine (TEA), 200 µM MgCl2, 0.1 mg/ml bovine serum albumin 
(BSA), 0.01 % Triton X-100] were added to a 384-well plate. After 15 min 
incubation at RT, 10 µl of Reagent A and 20 µl of Reagent B were added to 
the plate and the mixture was incubated for 30 min. Then fluorescence was 
measured at Varioskan LUX plate reader.  
 
4.4.  LsrK inhibition assay 
 
The selected LsrK inhibition assay was used in study I, II, III and IV to 
identify compounds with inhibitory activity on LsrK. Compounds were 
diluted in assay buffer [25 mM TEA, 200 µM MgCl2, 0.1 mg/ml BSA, 0.01 % 
Triton X-100] and plated into a 384-well plate. More details about 
concentrations and replicates are presented in paragraph 4.2. Then, 300 nM 
of purified protein and 300 µM DPD diluted in assay buffer were added and 
the assay was carried out as described in paragraph 4.3.1.   
 
4.5. Glycerol kinase inhibition assay 
 
Glycerol kinase inhibition assay was used in study I, II and III to 
preliminarily evaluate the selectivity of the positive hits identified by LsrK 
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inhibition assay. The set-up described in the paragraph 4.3. was used with 
300 nM glycerol kinase and 300 µM glycerol. 
 
4.6. Thermal shift assay 
 
In study II thermal shift assay was used to confirm the target engagement of 
the positive hits. 25 µl of a reaction mixture containing 2.5 µl of 1.73 µM 
LsrK, 2.5 µl of SYPRO orange dye and 10 µl of compounds at 5 
concentrations ranging from 0 to 300 µM in assay buffer was plated on a 96-
well plate. A sample containing LsrK and 1µM ATP was used as positive 
control. The assay was performed on a real-time polymerase chain reaction 
(PCR) thermocycler (Stratagene MX3005P QPCR System, Agilent 
Technologies, CA, USA) applying a gradient heating of 0.066 °Cs-1. 
 
4.7. AI-2 mediated QS interference assay based on  
β-galactosidase activity 
 
In study I, a cell-based AI-2 mediated QS interference assay based on E. coli 
LW7 pLW11 was performed to evaluate QS inhibition activity of rosolic 
acid, harpagoside and aurin tricarboxylic acid. The strain contains the 
pLW11 plasmid where the β-galactosidase gene is under control of 
lsrACDBFG, a QS responsive promoter. An overnight culture was diluted in 
fresh lysogenic broth (LB) and grown at 30°C till exponential phase. For the 
assay, a bacterial suspension containing 109 CFU/ml bacteria (2×final 
concentration) in PBS with or without 100 µg/ml phe-arg β-naphtylamide 
dihydrochloride (PAβN) was prepared (DPD-). Half of the suspension was 
supplemented with 40 µM DPD (2×final concentration) (DPD+). The 
compounds were diluted in PBS with and without 100 µg/ml PAβN to a final 
concentration of 100 and 20 µM (2×final concentration) and 50 µl for each 
sample were plated in triplicate in 96-well plate. DPD- suspension was 
added to half of the plate while the other half was filled up with DPD+ 
suspension. After 2 hours incubation at 37 °C under shaking, abs at 600 nm 
was measured with the Multiskan GO plate reader (Thermo Fisher Scientific, 
Finland). The plate was frozen overnight. The following day, detection mix 
including [60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 36 
mM β-mercaptoethanol, 6.7% PopCultureTM reagent, 1.1 mg/ml 2-
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nitrophenyl β-D-galactopyranoside (ONPG)] was added to the plate and the 
plate was incubated for 2 hours before reading the absorbance at 420 and 550 
nm. 
 
4.8. Luminescence-based AI-2 mediated QS interference assay  
 
4.8.1. Plasmid construction 
 
A luminescence–based bioreporter strain for the identification of AI-2 
mediated QS inhibitors was developed in study IV. The plasmid pLW11, 
containing β-galactosidase gene, under control of lsr promoter, was 
extracted from E. coli LW7 pLW11 and used as template for the amplification 
of the lsr promoter. The PCR product was cloned into pET-PesaRlux142, 
previously digested the esaR promoter. The pET-Plsrlux construct was 
transformed into Subcloning efficiency DH5α strain and then transferred 
into E. coli JW5503 or E. coli ATCC25922. 
 
4.8.2. Assay development and screening campaign 
 
E. coli JW5503 pET-Plsrlux was grown overnight and diluted 1:50 in fresh LB 
supplemented with the appropriate antibiotics. Bacteria were grown at 30 °C 
under shaking till exponential phase. Compounds were diluted at 200 µM 
(2×final concentration) in LB and 50 µl were plated in triplicate into 96 well-
plate (View Plate, PerkinElmer Winter St., Waltham, Massachusetts, USA). 
For negative and positive control wells, 50 µl of LB and 50 µl of LB 
supplemented with 4% glucose (2×final concentration), respectively, were 
plated in triplicate. 50 µl of a bacterial suspension containing 1×108 CFU/ml 
(2×final concentration) were added to the plate. The plate was incubated at 
37 °C for 3 hours under shaking and then Abs600 and luminescence were 
measured with Varioskan LUX plate reader.  
Compounds with QS inhibition ≥ 80 % and growth inhibition ≤ 40 % were 
selected for dose-response experiments and tested at 7 concentrations 




4.9. Data analysis 
 
S/B, SW and Z´ factor, quality parameters typically used for assay 
development and HTS, were calculated according to the following equations 
to evaluate assay performance [143,144]: 
S/B : µM/µm                                                                                                            (1)                                                                                                           
SW : (µM-μM)/SQRT[(σM2)+(σm2)]                                                                     (2)                                   
Z´ : 1 - [(3*σM+3*σm)/(│µM│-│µm│)]                                                               (3)                        
In the equations µM and µm represent the average for the maximum and 
minimum signals, respectively, whereas σM and σm represent the standard 
deviation. Z´ factor ≥ 0.5 indicates a good quality assay. 
The inhibition % was calculated according to equation 4 where X is the mean 
of the detected luminescence for the sample and XM and Xm represent 
respectively mean of the detected luminescence for the maximum and 
minimum control: 
Inhibition % : 100 × [(X-Xm)/(XM-Xm)]                                                               (4)                                                                                       
In study III the promiscuity index, PCIdx, based on PubChem activity 
profile, was calculated according to the following equation [145]: 
PCIdx = N(active)/N(tested)                                                                                  (5)                            
N(active) is the number of assays reported in PubChem where the analyzed 
compound has been classified as active whereas N(tested) is the total 
number of assays reported. 
The inhibition % for AI-2 mediated QS interference was calculated as 
follows 
Inhibition% = 100 – remaining activity %                                                           (6)                    
Wherein remaining activity % for the β-galactosidase based assay 
corresponds to [146]: 
Remaining activity %  = 100 × [MUs(DPD+) - MUc(DPD-)]/[MUc(DPD+) - 
MUc(DPD-)]                                                                                                            (7) 
And for the luminescence-based assay corresponds to: 
Remaining activity % = 100 × [(X-Xm)/(XM-Xm)]                                             (8)                         
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In the equation 7, MUs and MUc respectively correspond to the _ 
galactosidase activity expressed in Miller Unit (MU) calculated for the 
sample and the DMSO control, with (DPD+) and without DPD (DPD-). 
In the equation 8, X is the luminescence detected for the sample and XM and 
Xm are respectively the mean of the detected luminescence for the minimum 
























5. Results and discussion 
 
This chapter summarizes the main results of the studies which are presented 
in more detail in the attached publications (I-IV). 
Study I, II and III focused on the development of an enzyme-based assay 
and its application during screening campaigns to discover LsrK inhibitors. 
Overall, the work significantly improved the knowledge on LsrK and 
provided interesting compounds which can be used as starting points for the 
development of a new class of antivirulence agents based on LsrK inhibition. 
Article IV presents the development of a new bio-reporter strain for the 
identification of AI-2 mediated QS inhibitors which can contribute to the 
discovery of new classes of antivirulence agents. 
 
5.1. Target-based screening 
 
5.1.1. LsrK assay development 
 
LsrK is a bacterial kinase belonging to FGGY sugar kinase family which 
mediates an essential step in the AI-2 mediated QS in gut enteric bacteria 
[147]. In fact, the AI-2 phosphorylation by LsrK is essential for de-repressing 
the lsr promoter and beginning the QS cascade [140]. The LsrK crystal 
structure showed that the enzyme has two domains [148]. The domain II 
binds to ATP whereas the domain I binds to HPr, a phosphate carrier which 
contributes to phosphorylation of sugars internalized by PTS system. This 
further confirmed the essential role of LsrK in QS as it is subjected to a fine 
regulation. In fact, QS establishment depends on bacterial cellular density 
and the complex HPr/LsrK acts as a sensor. During the exponential phase, 
the sugar import is particularly intense so that HPr will be mainly present in 
the unphosphorylated form with an inhibitory effect on LsrK and 
consequently, on QS. The phosphorylated form of HPr is dominant in the 
stationary phase, when the population density is high and thus import of 
sugar is reduced. P-HPr correlates to an active form of LsrK, thus response 
to QS will be enhanced in stationary phase [149]. Protein-protein interaction 
appears thus to be a natural mechanism to inhibit LsrK and silence QS. 
Therefore it is legit to think that LsrK inhibition may lead to QS inactivation 
and consequent loss of virulence. 
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However, no systematic screening approach has previously been carried out 
against LsrK. Earlier reported assays to identify LsrK inhibitors include thin 
layer chromatography (TLC) with [γ-32P] or the detection of ATP 
consumption [150, 151]. However, radioactivity-based assays find limited 
applications in large screening campaigns due to the use of radiolabeled 
materials and the reported assays based on ATP consumption were not 
aiming to screen chemical libraries for LsrK inhibitors but rather to evaluate 
the effect of DPD modifications on its processing [164].  
To identify LsrK inhibitors by HTS, we designed a luminescence-based LsrK 
inhibition assay in 384-well plate format. As ATP-based methodologies are 
widely used to study kinases, two commercially available kits were 
compared: Kinase-Glo Max Luminescent kinase assay (Promega), based on 
the conversion of the remaining ATP in the reaction mixture into light, and 
ADP-Quest (DiscoverX), based on the conversion of ADP, formed during the 
reaction, into a fluorescent probe (Table 4). Read-out stability and DMSO 
tolerance were determined and compared for both kits. Sensitivity and 
automation-compatibility were also taken into account. 
Table 4: Comparison of Kinase-Glo Max Luminescence kinase assay and 
ADP-Quest kit 
Kinase-Glo Max Luminescence 
kinase assay 
ADP-Quest 
• ATP depletion method 
• Sensitive (S/B ≥60 ) 
• ATP up to 500 µM 
• Signal stable up to 5 hours 
• DMSO tolerance up to 5% 
• easily automatable  
• ADP formation 
• Low sensitivity (S/B = 4) 
• ATP up to 200 µM 
• Signal stable up to 1 hour 
• DMSO tolerance up to 5% 
 
Due to the high sensitivity and stability, the final assay was based on 
Kinase-Glo Max Luminescence kinase assay, according to the following 




Figure 5: Schematization of the LsrK inhibition assay protocol. 
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5.1.2. Screening campaigns 
 
The described LsrK inhibition assay was used to perform screening of 3 
chemical libraries  
In study I, results from the screening campaign on the MicroSource 
Spectrum library are reported (Table 5). The library contains 2000 molecules 
including synthetic compounds, which have reached clinical trials phase or 
are approved drugs, and a variety of natural products ensuring high 
structural and activity diversity. The primary screening yielded 107 
compounds which were tested in a glycerol kinase inhibition assay for 
preliminary assessment of selectivity. The same set was also re-tested in the 
LsrK inhibition assay at a lower concentration to estimate potency. The 
results of the two tests were compared and 47 compounds were selected for 
follow-up studies. Among those, 25 were excluded as they were reported in 
literature as unspecific inhibitors or antibacterials. A final set of 22 
compounds was tested for dose-response (I, Fig 3). Among those, rosolic 
acid and harpagoside confirmed their activity as QS inhibitors in a cell-based 
AI-2 mediated QS interference assay in combination with efflux blocking 
PAβN [152].  
In study II, the design of a 3D LsrK homology model and its application for 
the virtual screening of a commercially available database is described. The 
model was built using as a template the crystal structure of xylulokinase and 
glycerol kinase as they were found to be LsrK homologs by PSI-BLAST 
sequence analysis [153]. The model was validated by Ramachandran plot, 
ModVal, ERRAT and the RMSD (root mean square deviation) with 
templates and used for the virtual screening of the FIMM database including 
132 566 compounds. Compared to in vitro screening, virtual screening offers 
the chance to rapidly explore chemically diverse databases and select 
compounds with high probability to bind the target protein. 104 compounds 
were selected and tested against LsrK in an inhibition assay resulting in 2 
active compounds, meclofenamic acid and IOX1, which were used as 
templates for the selection of analogues. The second round of screening 
resulted in a total of 6 hits which belong to the meclofenamic acid series. 5 
among those were confirmed to bind to LsrK by thermal shift assay (Table 
5). 
In study III, the synthesis and biological evaluation of DPD analogues is 
presented. The advantage of the ligand-based approach is the selectivity 
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ensured by the targeting of the unique enzymatic catalytic site. However, 
since DPD is an unstable molecule which exists as several structures due to 
cyclization [154], the design and synthesis of analogues is complex. 
Differently than previously exploited analogues [155, 156, 157, 158] the 
synthetized analogues support modification on the diketo-moiety which is 
incorporated into the heteroaromatic ring to increase stability of the 
molecule. 4 compounds, belonging to the pyrazole-containing series were 
active against LsrK with an IC50 ranging between 119 and 475 µM (Table 5). 
 
Table 5: Active compounds and their IC50 identified by LsrK inhibition assay 
in studies I, II and III. Data are presented as average ± SD from two 
independent experiments (n=4) 
 

































475 ± 11 
12b 
 
384 ± 15 
13a 
 





284 ± 19 
 
The random screening provided the best hits which also showed activity as 
QS inhibitors in the cell-based assay. To our knowledge, rosolic acid and 
harpagoside are currently the most promising scaffolds for the development 
of a new class of LsrK inhibitors to be used as antivirulence agents. But, the 
high IC50 values and the need of efflux pump blocking PAβN hamper the 
interest of these compounds for in vivo studies. However, additional studies 
may provide a better understanding of the molecular interaction between 
these compounds and LsrK, and lead to the identification of a functional 
structural motif. Chemical support will also be needed to improve potency 
and to enhance cellular accumulation.  
Virtual screening approach provided 6 active compounds which all belong 
to the meclofenamic acid series highlighting the presence of a significant 
structural motif. The compounds may act as ATP competitors as their 
potency increases at lower ATP concentrations. The ligand-based approach 
resulted in 4 positive hits from the pyrazole containing analogues with 
considerably low potency. Although those compounds are too weak to be 
considered as candidates for the development of antivirulence agents, they 
offered an important hint to better understand the interaction between LsrK 
and DPD and the contributions of different substituents to the binding. SAR 
studies performed on the positive hits from virtual screening and ligand-
based approach highlighted the importance of Thr275 which is located near 
the LsrK binding site. In fact, the activity of the most effective compound 
from study II was explained by the formation of H bond with Thr275 and 
surrounding amino acid near the binding site (II, Fig S15). The same 
interaction was observed for compound 13a (III) which is the most active 
compounds among the DPD analogues described in study III (III, Fig 5). 
Active compounds from both studies also showed interaction with Phe276 
and Gln278 although their potency was inferior to compounds interacting 
with Thr275. Thr275 may thus have an essential role for the catalytic activity 
of LsrK. Study III also highlighted the stabilizing role of acetals which form 
electrostatic interactions with LsrK binding site whereas diols form 
repulsive interactions.  
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Overall these considerations broaden our knowledge on LsrK and may 
support the design of new compounds with improved activity and better 
pharmacokinetic properties for in vivo studies and clinical applications. 
 
5.2. Cell-based assay development and screening 
 
5.2.1.  Development of a bioreporter strain for QS inhibition studies 
 
Cell-based assays are essential screening tools to confirm the activity of hits 
selected by target-based assays in more physiological conditions. They can 
also be used as direct screening platforms for the identification of 
compounds which are active on the pathway of interest even if targeting an 
unknown component. 
Previously reported cell-based assays for the identification of AI-2 mediated 
QS inhibitors include E. coli LW7 pLW11, a bioreporter strain based on β-
galactosidase expression in response to QS activation, and AI2-QQ.1, a 
bioreporter strain based on the toxin/antitoxin system. In the first example, 
β-galactosidase is under control of the lsr operon and will be expressed 
when the QS system is active. The enzyme can be quantified by following 
the formation of a colored product, derived from the cleavage of ONPG. A 
QS inhibitor will prevent β-galactosidase expression and consequently no 
colored product will be detected [146]. The length and complexity of the 
protocol, together with the need of a secondary control strain to verify the 
interference of the tested compounds with β-galactosidase activity, are 
significant limitations for the use of this set-up for screening. The AI2-QQ.1 
strain expresses the lethal gene ccdb from E. coli in response to the activation 
of a QS responsive promoter. Thus, when QS is active, the protein is 
expressed, and the cell dies whereas, the addition of QS inhibitors, will 
result in a viable cell [159]. It also requires a control strain to assess 
compound toxicity. Additionally, both set-ups need the addition of 
exogenous DPD with an increase in the cost and artificiality of the system. 
In study IV, a new cell-based assay for the identification of AI-mediated QS 
inhibitors is presented. The concept is based on the expression of luciferase 
under control of lsr promoter. The construct pET-Lsrlux was generated 
starting from the commercially available plasmid pET-pEsaRlux by 
replacing the EsaR promoter with the lsr promoter sequence. The new 
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plasmid was cloned into E. coli JW5503, an efflux pump defective strain. In 
fact, as one of the main limitations in the identification of new antibiotics is 
the low intracellular concentration due to the expulsion by the efflux pump 
system, this strain will allow the intracellular accumulation of test 
compounds and thus facilitate the identification of new hits [160]. Compared 
to previously reported assays for the identification of AI-2 mediated QS 
inhibitors, the new bioreporter strain produces endogenous DPD so that no 
external addition is needed reproducing more physiological conditions and 
reducing the costs. It also allows the simultaneous identification of toxic 
compounds as detection of luminescence can be coupled with detection of 
absorbance to determine viability so that no additional tests are needed for 
this purpose.  
In the assay development phase, optimal bacterial concentration, effect of 
DMSO and read-out stability were evaluated. The finalized protocol 
included a starting bacterial concentration of 5^107 CFU/mL and an 
incubation time of 3 hours. In fact, the Z’ factor reached a value of 0.92 after 
3 hours and remained stable (≥0.84) up to 7 hours ensuring an acceptable 
time window to detect the signal. The DMSO concentration must be kept 
≤2% as higher concentrations affect the luminescence. 
 
5.2.2. Screening campaign 
 
To validate the assay, we tested 91 compounds designed to target the ATP 
binding site of DNA gyrase [161]. Our hypothesis was that these compounds 
would thus be capable to bind also to the LsrK ATP binding site. The entire 
set was tested in the LsrK inhibition assay and on the new bioreporter assay 
in parallel and the results were compared.  
IC50 for LsrK was determined for 29 compounds, ranging from 8 to 147 µM. 
Among those, 6 hits were confirmed to be active as inhibitors in the cell-
based AI-2 mediated QS interference assay (Table 6). UL-03 and UL-21 were 
the best compounds with an IC50 in the submicromolar range in the QS 
inhibition assay (IV, Fig S4). However, all the compounds shower higher 
potency in the cell-based assay. This might be due to structural differences 
observed in the catalytic domains of LsrK from S. thyphimurium, used in the 
target-based assay, and LsrK from E. coli used in the AI-2 interference assay, 
which affects the interaction with small molecules [162]. 
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Table 6: Hits and their IC50 determined by LsrK inhibition assay and AI-2 
mediated QS interference assay. Data are presented as average ± SD from 









18± 2 10± 0.4 
UL-06 
 
147± 12 2 ±0.2 
UL-03 
 
18 ±2 0.6± 0.1 
UL-19 
 
29±2 1.0± 0.1 
UL-21 
 
15± 1 0.4 ±0.2 
UL-09 
 
78± 1 17± 2 
 
The cell-based AI-2 mediated QS interference assay also identified 18 hits 
which were not active on LsrK. Those compounds may target other 
components involved in the pathway and thus be a potential starting point 
for the development of a new class of QS inhibitors. However, additional 
investigations are needed to identify the target and clarify the mode of 
action as well as to improve their cell accumulation. In fact, none of the 
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compounds showed activity when tested on E. coli ATCC 255922 with 
regular efflux pump activity. 
Although the study did not provide any suitable candidate for future clinical 
applications, it described the design and validation of a new effective tool 
for QS inhibitors discovery as the assay can be easily scaled-up and 
automated to support larger screening campaigns. Furthermore, it proved 
the efficacy of the new format to support the confirmation of hits selected by 
target-based assay as well as the identification of new molecules active on 




Antivirulence agents have the potential to revolutionize the treatment of 
bacterial infections by targeting virulence factors rather than viability and 
thus reducing selective pressure for resistant mutants.  
The aim of this thesis was to support the discovery of new QS inhibitors by 
targeting LsrK, a key enzyme for the processing of autoinducer-2 in enteric 
bacteria. Study I, II and III report data related to three screening campaigns 
performed for the identification of LsrK inhibitors. The major difference 
among the three studies is the nature of the screened libraries. In fact, for 
study I, the chosen library was unrelated to LsrK and was selected to 
investigate structurally diverse compounds aiming to isolate meaningful 
structural motifs for LsrK inhibition. In study II, the set of compounds for 
the screening was selected by virtual screening using a 3D LsrK model to 
maximize the chance of interaction with the target enzyme by using a target-
based approach. The compounds screened in study III were synthetic DPD 
analogues which were designed to target the LsrK substrate binding pocket. 
Although none of the studies provided significant hits for future follow-up 
studies and drug design, they broaden our knowledge on LsrK and its mode 
of action by highlighting the significance of Thr275 for the enzymatic activity 
of LsrK and thus providing interesting hints for future screening campaigns 
and drug design. Additionally, rosolic acid and harpagoside identified as 
LsrK inhibitors in study I, were also effective on the AI-2 mediated QS 
interference assay proving that LsrK inhibition may indeed lead to the 
inactivation of the pathway. 
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Aiming to support the discovery of AI-2 mediated QS inhibitors, study IV 
described the assay development and validation of a new AI-2 mediated QS 
interference assay based on the emission of luminescence in response to QS 
activation by a genetically modified E. coli JW5503. The assay has been 
proven to be useful as complementary assay to confirm the activity of 
compounds selected by target-based assay but also as independent 
screening tool for a fast and easy identification of QS inhibitors. In fact the 
same set of 91 compounds, chosen for their potential to target the ATP 
binding pocket of LsrK, were tested in both the target-based and cell-based 
assay providing two sets of active hits. The first set includes 6 compounds 
which were also active against LsrK and thus were confirmed to be QS 
inhibitors by interfering with the kinase activity. The second set includes 18 
compounds which were exclusively active in the cell-based assay and may 
thus target other elements in the pathway which play an essential role and 
deserve to be further investigated.  
Based on the overall results of these studies, future research on LsrK 
inhibitors should be addressed to better understand the mode of action by 
using the found inhibitors as starting points. A synergistic effort among 
bioinformatic, chemistry and biology will be needed to advance in the 
selection and design of more effective compounds with improved 
permeability but also in the optimization and validation of new screening 
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